BACKGROUND: Despite increased risk for coronary artery disease and acute myocardial infarction (AMI), smokers have a paradoxically lower mortality after thrombolysis for AMI than non-smokers. We determined the clinical risk profiles and coronary flow characteristics of patients in the TIMI trials according to smoking status, focusing on microvascular flow. METHODS: Among 2,573 patients in the TIMI 4, 10A, 10B and TIMI 14 trials, epicardial flow post-thrombolysis was measured using angiographic TIMI flow grades and the corrected TIMI frame count (CTFC). Microvascular flow was measured by TIMI Myocardial Perfusion Grade (TMPG) and, in TIMI 14, the percentage of ST segment resolution. RESULTS: Clinically, the mean age (54 vs. 62 years), the prevalence of diabetes mellitus (11% vs. 16%) and hypertension (26% vs. 40%), and the 30-day mortality (2.6% vs. 6.2%) were lower among smokers than non-smokers (all p < or = 0.001). Angiographically, single-vessel disease (48% vs. 40%) and non-left anterior descending infarct arteries (65.4% vs. 60.8%) were more common among smokers (both p < or = 0.01). Epicardial TIMI grade 3 flow was achieved more often in smokers than non-smokers (61% vs. 56%) and the CTFC was faster (34 vs. 37 frames/sec, both p < or = 0.01), especially in LAD lesions. However, the frequency of normal microvascular flow (TMPG 3) was similar among smokers and non-smokers (24% vs. 29%, p = 0.16), as was the frequency of complete ST segment resolution (50% vs. 46%, p = 0.29). CONCLUSIONS: Smokers have lower mortality after AMI than non-smokers, due in large part to lower clinical risk profiles and faster epicardial flow. Differences in tissue-level perfusion do not appear to contribute to lower mortality in smokers.
BACKGROUND: Despite increased risk for coronary artery disease and acute myocardial infarction (AMI), smokers have a paradoxically lower mortality after thrombolysis for AMI than non-smokers. We determined the clinical risk profiles and coronary flow characteristics of patients in the TIMI trials according to smoking status, focusing on microvascular flow. METHODS: Among 2,573 patients in the TIMI 4, 10A, 10B and TIMI 14 trials, epicardial flow post-thrombolysis was measured using angiographic TIMI flow grades and the corrected TIMI frame count (CTFC). Microvascular flow was measured by TIMI Myocardial Perfusion Grade (TMPG) and, in TIMI 14, the percentage of ST segment resolution. RESULTS: Clinically, the mean age (54 vs. 62 years), the prevalence of diabetes mellitus (11% vs. 16%) and hypertension (26% vs. 40%), and the 30-day mortality (2.6% vs. 6.2%) were lower among smokers than non-smokers (all p < or = 0.001). Angiographically, single-vessel disease (48% vs. 40%) and non-left anterior descending infarct arteries (65.4% vs. 60.8%) were more common among smokers (both p < or = 0.01). Epicardial TIMI grade 3 flow was achieved more often in smokers than non-smokers (61% vs. 56%) and the CTFC was faster (34 vs. 37 frames/sec, both p < or = 0.01), especially in LAD lesions. However, the frequency of normal microvascular flow (TMPG 3) was similar among smokers and non-smokers (24% vs. 29%, p = 0.16), as was the frequency of complete ST segment resolution (50% vs. 46%, p = 0.29). CONCLUSIONS: Smokers have lower mortality after AMI than non-smokers, due in large part to lower clinical risk profiles and faster epicardial flow. Differences in tissue-level perfusion do not appear to contribute to lower mortality in smokers.
Authors: C P Cannon; C M Gibson; C H McCabe; A A Adgey; M J Schweiger; R F Sequeira; G Grollier; R P Giugliano; M Frey; H S Mueller; R M Steingart; W D Weaver; F Van de Werf; E Braunwald Journal: Circulation Date: 1998 Dec 22-29 Impact factor: 29.690
Authors: D Hasdai; A Lerman; C S Rihal; D A Criger; K N Garratt; A Betriu; H D White; E J Topol; C B Granger; S G Ellis; R M Califf; D R Holmes Journal: Am Heart J Date: 1999-04 Impact factor: 4.749
Authors: E M Antman; C M Gibson; J A de Lemos; R P Giugliano; C H McCabe; P Coussement; I Menown; C A Nienaber; T C Rehders; M J Frey; R Van der Wieken; D Andresen; J Scherer; K Anderson; F Van de Werf; E Braunwald Journal: Eur Heart J Date: 2000-12 Impact factor: 29.983
Authors: C P Cannon; C H McCabe; C M Gibson; M Ghali; R F Sequeira; G R McKendall; J Breed; N B Modi; N L Fox; R P Tracy; T W Love; E Braunwald Journal: Circulation Date: 1997-01-21 Impact factor: 29.690
Authors: Peter C Kievit; Marc A Brouwer; Gerrit Veen; Wim R M Aengevaeren; Freek W A Verheugt Journal: J Thromb Thrombolysis Date: 2008-06-26 Impact factor: 2.300
Authors: Damir Fabijanić; Lovel Giunio; Viktor Culić; Ivo Bozić; Duska Martinović; Dinko Mirić Journal: Ann Saudi Med Date: 2005 Mar-Apr Impact factor: 1.526